ScoreWhy is Jagsonpal Pharmaceuticals Ltd ?
1
The company is Net-Debt Free
2
Poor long term growth as Net Sales has grown by an annual rate of 6.92% and Operating profit at 16.09% over the last 5 years
- NET SALES(Q) Highest at Rs 82.23 cr
- PBDIT(Q) Highest at Rs 17.24 cr.
- PBT LESS OI(Q) Highest at Rs 14.85 cr.
3
With ROE of 18.6, it has a Very Expensive valuation with a 6.3 Price to Book Value
- The stock is trading at a discount compared to its peers' average historical valuations
- Over the past year, while the stock has generated a return of 1.26%, its profits have risen by 12.5% ; the PEG ratio of the company is 2.5
4
Despite the size of the company, domestic mutual funds hold only 0% of the company
- Domestic mutual funds have capability to do in-depth on-the-ground research on companies- their small stake may signify either they are not comfortable at the price or the business
Real-Time Research ReportHow much should you hold?
- Overall Portfolio exposure to Jagsonpal Pharma should be less than 10%
- Overall Portfolio exposure to Pharmaceuticals & Biotechnology should be less than 30%
(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)
When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock
Is Jagsonpal Pharma for you?
Medium Risk, Medium Return
Absolute
Risk Adjusted
Volatility
Jagsonpal Pharma
1.19%
0.04
33.11%
Sensex
-4.88%
-0.36
13.50%
Quality
Management Risk
Growth
Capital StructureQuality key factors
Factor
Value
Sales Growth (5y)
6.92%
EBIT Growth (5y)
16.09%
EBIT to Interest (avg)
34.63
Debt to EBITDA (avg)
0.30
Net Debt to Equity (avg)
-0.59
Sales to Capital Employed (avg)
1.31
Tax Ratio
25.16%
Dividend Payout Ratio
29.99%
Pledged Shares
0
Institutional Holding
2.92%
ROCE (avg)
36.15%
ROE (avg)
16.16%
ValuationValuation Key Factors 
Factor
Value
P/E Ratio
34
Industry P/E
37
Price to Book Value
6.34
EV to EBIT
27.98
EV to EBITDA
23.75
EV to Capital Employed
14.17
EV to Sales
4.94
PEG Ratio
2.52
Dividend Yield
1.04%
ROCE (Latest)
44.66%
ROE (Latest)
18.60%
Loading Valuation Snapshot...
TechnicalsTechnical key factors
Indicator
Weekly
Monthly
MACD
Bullish
Bullish
RSI
No Signal
No Signal
Bollinger Bands
Bullish
Bullish
Moving Averages
Bullish (Daily)
KST
Bullish
Mildly Bearish
Dow Theory
Mildly Bullish
No Trend
OBV
Mildly Bearish
Bullish
Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned 
Financial Trend8What is working for the Company
NET SALES(Q)
Highest at Rs 82.23 cr
PBDIT(Q)
Highest at Rs 17.24 cr.
PBT LESS OI(Q)
Highest at Rs 14.85 cr.
PAT(Q)
Highest at Rs 13.19 cr.
EPS(Q)
Highest at Rs 2.00
0What is not working for the Company
NO KEY NEGATIVE TRIGGERS
Loading Valuation Snapshot...
Here's what is working for Jagsonpal Pharma
Net Sales - Quarterly
Highest at Rs 82.23 cr
in the last five quartersMOJO Watch
Near term sales trend is positive
Net Sales (Rs Cr)
Operating Profit (PBDIT) - Quarterly
Highest at Rs 17.24 cr.
in the last five quartersMOJO Watch
Near term Operating Profit trend is positive
Operating Profit (Rs Cr)
Profit Before Tax less Other Income (PBT) - Quarterly
Highest at Rs 14.85 cr.
in the last five quartersMOJO Watch
Near term PBT trend is positive
PBT less Other Income (Rs Cr)
Profit Before Tax less Other Income (PBT) - Quarterly
At Rs 14.85 cr has Grown at 24.8% (vs previous 4Q average)
over average PBT of the previous four quarters of Rs 11.90 CrMOJO Watch
Near term PBT trend is positive
PBT less Other Income (Rs Cr)
Profit After Tax (PAT) - Quarterly
Highest at Rs 13.19 cr.
in the last five quartersMOJO Watch
Near term PAT trend is positive
PAT (Rs Cr)
Earnings per Share (EPS) - Quarterly
Highest at Rs 2.00
in the last five quartersMOJO Watch
Increasing profitability; company has created higher earnings for shareholders
EPS (Rs)
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."
